Evidence map›Paper›PMID 41848776›Full record

ArticleArchives of virology2026

Specific features of the infection caused by SARS-CoV-2 variants in Vero cell culture.

Alexander Chepurnov, Svetlana Miroshnichenko, Mickhail Ivanov, Mariya Solomatina, Elena Kazachinskaia, Evgeniya Kazachkova, Yulia Kononova, Mickhail Voevoda, Arseniya Shelemba, Oksana Mishchenko and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Alexander ChepurnovInstitute of Virology, Federal Research Center of Fundamental and Translational Medicine, Siberian Branch, Russian Academy of Sciences, Novosibirsk, Russian Federation.
Svetlana MiroshnichenkoInstitute of Virology, Federal Research Center of Fundamental and Translational Medicine, Siberian Branch, Russian Academy of Sciences, Novosibirsk, Russian Federation.
Mickhail IvanovVector-Best, Novosibirsk, Russian Federation.
Mariya SolomatinaInstitute of Virology, Federal Research Center of Fundamental and Translational Medicine, Siberian Branch, Russian Academy of Sciences, Novosibirsk, Russian Federation.
Elena KazachinskaiaInstitute of Virology, Federal Research Center of Fundamental and Translational Medicine, Siberian Branch, Russian Academy of Sciences, Novosibirsk, Russian Federation.
Evgeniya KazachkovaInstitute of Virology, Federal Research Center of Fundamental and Translational Medicine, Siberian Branch, Russian Academy of Sciences, Novosibirsk, Russian Federation.
Yulia KononovaInstitute of Virology, Federal Research Center of Fundamental and Translational Medicine, Siberian Branch, Russian Academy of Sciences, Novosibirsk, Russian Federation.
Mickhail VoevodaInstitute of Virology, Federal Research Center of Fundamental and Translational Medicine, Siberian Branch, Russian Academy of Sciences, Novosibirsk, Russian Federation.
Arseniya ShelembaVector-Best, Novosibirsk, Russian Federation.
Oksana Mishchenko48th Central Research Institute of the Ministry of Defense of the Russian Federation, Sergiyev Posad 6, Russian Federation.
Aleksey Surovyatkin48th Central Research Institute of the Ministry of Defense of the Russian Federation, Sergiyev Posad 6, Russian Federation.
Marina GulyaevaInstitute of Virology, Federal Research Center of Fundamental and Translational Medicine, Siberian Branch, Russian Academy of Sciences, Novosibirsk, Russian Federation. mgulyaeva@gmail.com.ORCID http://orcid.org/0000-0003-3945-5339
Alexander ShestopalovInstitute of Virology, Federal Research Center of Fundamental and Translational Medicine, Siberian Branch, Russian Academy of Sciences, Novosibirsk, Russian Federation.

Funding

Russian Science Foundation № 23-64-00005 «Genomics and evolution of viral pathogens causing the most common respiratory diseases»
6 · The paper itself

Abstract

Variants of SARS-CoV-2 differ in pathogenicity. Vero E6 cells are used to isolate, propagate, and study many viruses, including SARS-CoV-2. The aim of this work is to evaluate morphological differences during infection, and their relationships with the dynamics of viral titer. The cytopathic effect of the SARS-CoV-2 Wuhan-like variant was found to mainly follow an apoptotic pattern in 83 ± 6.1% of the cells. Infection resulted in near complete destruction of the cell monolayer. The maximum titer of the Wuhan variant reached 6.2 ± 0.2 log10 TCID50/ml on 4 d.p.i. At an inoculation dose of 3.5 log10 TCID50/ml. During infection with the delta variant (infection dose 4 = log10 TCID50/ml), up to 30% of cells remained alive, and cell death was accompanied by the formation of necrotic foci involving 41 ± 7.8% cells, and apoptosis of 30 ± 9.4% cells, with maximum titer reaching 5 ± 0.3 log10 TCID50/ml on day 5. In case of Omicron infection (infection dose = 3 log10 TCID50/ml), 90% cells survived, and for the rest 10% of cells the infection followed the classical pattern of apoptosis. At 5 d.p.i., the monolayer remained well preserved, but the morphology of all cells was changed suggested a wide infection of Vero cell culture with the Omicron variant. The maximum titer was 4.2 ± 0.3 log10 TCID50 on day 5. The higher doses were preferable for virus replication with Wuhan-like and Omicron viruses infection. For delta variant lower dose showed more effectivity as necrotic pattern of cell death was observed.

Indexed as

COVID-19SARS-CoV-2AnimalsApoptosisChlorocebus aethiopsCytopathogenic Effect, ViralHumansVero CellsViral LoadVirus ReplicationApoptosisCytopathic effect in monolayer cell cultureDelta and Omicron variantsNecrosisSARS-CoV-2Wuhan-like

Identifiers

PMID41848776

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.